---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-007077"
form_type: "8-K"
ticker: "KLRS"
cik: "0001754068"
company_name: "Kalaris Therapeutics, Inc."
filed_at: "2025-01-15T23:59:59+00:00"
generated_at: "2026-05-28T01:14:59.252932+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# AlloVir effects 1-for-23 reverse stock split effective Jan 15, 2025

## Summary
- Reverse split at 1-for-23 ratio, approved by board on Jan 9 after stockholder vote.
- Effective 4:05 pm ET Jan 15; trading on split-adjusted basis Jan 16 under ALVR.
- No fractional shares; cash in lieu based on Jan 15 closing price.
- Reverse split is part of preparations for proposed merger with Kalaris Therapeutics.
- New CUSIP number 019818202; par value and authorized shares unchanged.

## SEC filing metadata
- accession: 0001193125-25-007077
- form_type: 8-K
- ticker: KLRS
- cik: 0001754068
- company_name: Kalaris Therapeutics, Inc.
- filed_at: 2025-01-15T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 3.03, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1754068/000119312525007077/0001193125-25-007077-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1754068/000119312525007077/d900097d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-007077
- JSON: https://secwatch.observer/filing/0001193125-25-007077.json
- Plain text: https://secwatch.observer/filing/0001193125-25-007077.txt

## Key facts
- Governance Changes
  Kalaris Therapeutics, Inc.: Reverse stock split of common stock at 1-for-23 ratio via Certificate of Amendment to Third Amended and Restated Certificate of Incorporation (effective 2025-01-15).
  - Change: charter amendment
  - Effective: 2025-01-15
  source text: On January 15, 2025, AlloVir, Inc. (“AlloVir”) filed an amendment (the “Certificate of Amendment”) to its Third Amended and Restated Certificate of Incorporation, as amended and/or restated from time to time, to effectuate a reverse stock split of AlloVir’s issued and outstanding shares of common stock, par value $0.0001 per share (the “Common Stock”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1754068/000119312525007077/0001193125-25-007077-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.